Angiogenesis Is Associated With Aggressive Biology That Counterbalances With Tumor Immunogenicity in Hepatocellular Carcinoma
World Journal of Oncology · 2025-04 · 16 (2) · 173-181
DOI: 10.14740/wjon2009 ↗At a glance
Journal article in World Journal of Oncology, 2025-04. Written by Raj Vaghjiani and 4 co-authors. Institution: Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Cited 4 times so far (Crossref). The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Hepatocellular carcinoma (HCC) is an arterialized tumor; thus, anti-angiogenesis targeted therapy is in clinical practice. Herein, we hypothesized that HCC with high angiogenesis is biologically aggressive with worse survival.
Methods
Angiogenesis score (AS) was derived from the Molecular Signatures Database (MSigDB) Hallmark Angiogenesis Gene Set, and median was used to divide high versus low groups. Transcriptome of HCC patients of The Cancer Genome Atlas (TCGA, n = 386) and GSE76427 (n = 115) cohorts were analyzed.
Results
High AS correlated with angiogenesis-related gene expressions. Both microvascular and lymphatic endothelial cell infiltrations were higher in high angiogenesis HCC. Surprisingly, no survival difference was seen with varying levels of angiogenesis. High angiogenesis significantly enriched tumor aggravating signaling pathways: glycolysis, Notch, Hedgehog, KRAS, epithelial mesenchymal transition, and transforming growth factor-beta (TGF-β) in Gene Set Enrichment Analysis (GSEA), but also infiltrated less CD8+ T cells and T-helper 1 cells, and higher M1 macrophages and conventional dendritic cells (cDCs) with elevated cytolytic activity score in both cohorts. In agreement, immune response-related gene sets: inflammatory response, tumor necrosis factor-alpha (TNF-α) signaling, allograft rejection, interferon-alpha, and interferon-gamma were all enriched to high angiogenesis HCC. Programmed cell death protein 1 (PD1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) were higher in high angiogenesis HCC in TCGA, but not in GSE76427 cohort.
Conclusions
Angiogenesis quantified using transcriptome of HCC patients demonstrated that it is associated with aggressive biology but also with tumor immunogenicity and immune response that counterbalance and did not reflect in survival. Given high expression of immune checkpoint molecules, we cannot help but speculate that immunotherapy may be useful for high angiogenesis HCC patients.
Subjects
Author keywords
Authors and institutions
- Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- These authors contributed equally to this work.
- Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
- Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA.
- Department of Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Cite
APA
Vaghjiani, R., Wu, R., Tung, K. H., Ishikawa, T., & Takabe, K. (2025). Angiogenesis Is Associated With Aggressive Biology That Counterbalances With Tumor Immunogenicity in Hepatocellular Carcinoma. World Journal of Oncology, 16(2), 173-181. https://doi.org/10.14740/wjon2009
Vancouver
Vaghjiani R, Wu R, Tung KH, Ishikawa T, Takabe K. Angiogenesis Is Associated With Aggressive Biology That Counterbalances With Tumor Immunogenicity in Hepatocellular Carcinoma. World Journal of Oncology. 2025;16(2):173-181. doi:10.14740/wjon2009
BibTeX
@article{Vaghjiani2025,
author = {Vaghjiani, Raj and Wu, Rongrong and Tung, Kaity H and Ishikawa, Takashi and Takabe, Kazuaki},
title = {Angiogenesis Is Associated With Aggressive Biology That Counterbalances With Tumor Immunogenicity in Hepatocellular Carcinoma},
journal = {World Journal of Oncology},
year = {2025},
volume = {16},
number = {2},
pages = {173--181},
doi = {10.14740/wjon2009}
}
EUVIMED